CAJ | 학술논문

目的：比较分析多西紫杉醇单周与三周方案对转移性乳腺癌的有效性与安全性。方法对Pubmed、Co-chrane library、EMbased、CNKI、ASCO会议以及WHO官网进行相关文献搜索，检索截止时间为2013年3月11日。纳入有关多西紫杉醇单周与三周方案安全性与有效性的随机对照试验。结果共6个研究包括5篇全文和一篇会议纳入meta分析。多西紫杉醇单周方案与三周方案相比，无论在ORR、PFS、OS等方面均无统计学差异。在安全性分析中，单周方案3～4级中性粒细胞减少性发热的发生率显著低于三周方案（纳入3篇文献，共356例患者，OR 0．16，95％CI 0．06～0．43，P＜0．001）。同样中性粒细胞减少以及神经毒性的发生率单周方案也显著降低。结论多西紫杉醇单周化疗方案对转移性乳腺癌患者的有效性与三周方案相同，但鉴于单周方案的不良反应发生率低、耐受性好，老年患者或一般情况较差的患者更适合单周方案化疗。
목적：비교분석다서자삼순단주여삼주방안대전이성유선암적유효성여안전성。방법대Pubmed、Co-chrane library、EMbased、CNKI、ASCO회의이급WHO관망진행상관문헌수색，검색절지시간위2013년3월11일。납입유관다서자삼순단주여삼주방안안전성여유효성적수궤대조시험。결과공6개연구포괄5편전문화일편회의납입meta분석。다서자삼순단주방안여삼주방안상비，무론재ORR、PFS、OS등방면균무통계학차이。재안전성분석중，단주방안3～4급중성립세포감소성발열적발생솔현저저우삼주방안（납입3편문헌，공356례환자，OR 0．16，95％CI 0．06～0．43，P＜0．001）。동양중성립세포감소이급신경독성적발생솔단주방안야현저강저。결론다서자삼순단주화료방안대전이성유선암환자적유효성여삼주방안상동，단감우단주방안적불량반응발생솔저、내수성호，노년환자혹일반정황교차적환자경괄합단주방안화료。
Objective To study the efficacy and toxicity of weekly versus 3-weekly docetaxel regimens for metastatic breast cancer .Methods Pubmed,Cochrane library ,EMbased database ,ASCO annual meeting abstracts ,WHO website ( ongoing studies) and CNKI database were searched for relevant publications up to March 11,2013.Randomized controlled studies compa-ring weekly with 3-weekly docetaxel in MBC patients were studied .Results 6 eligible trials including 5 full-text articles and 1 conference abstracts were included in this systematic review .No significant differences were observed between weekly versus 3-weekly docetaxel in objective response rate ( ORR) ,progression free survival ( PFS) or overall survival ( OS) .With regard to the toxicity profile,the incidence of grade 3 ~4 neucopenic fever was notably lower among patients receiving weekly docetaxel (3 studies,356 patients,pooled OR 0.16,95%CI 0.06-0.43,P<0.001).The incidence of grade 3~4 neucopenia and neurotoxicity was also significantly lower in the weekly docetaxel regimen .Conclusion Weekly docetaxel provides equal effects as the stand-ard 3-weekly regimen for MBC patients .Considering its preferred toxicity profiles , weekly docetaxel regimen might be a better choice for elderly patients or those with poor performance status .